poisar

Stocks · News reference

8-K filing — Clene Inc. (CLNN)

SEC EDGARSEC EDGAR

Filed: 2026-10-20 AccNo: 0001437749-26-032960 Size: 221 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNot Specified

    Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

    Clene Inc. (Nasdaq: CLNN) announced the submission of a New Drug Application (NDA) to the FDA in October 2026 seeking accelerated approval of CNM-Au8 for treating amyotrophic lateral sclerosis (ALS). The submission is based on neurofilament light chain biomarker data and clinical outcomes. The company plans to continue with a confirmatory Phase 3 RESTORE-ALS study while awaiting FDA review.